TITLE

Better adherence would be boon for pharmaceutical industry

PUB. DATE
January 2013
SOURCE
Chain Drug Review;1/7/2013, Vol. 35 Issue 1, p70
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article informs about the report which provides insights into the significant revenue loss to pharmaceutical firms in the U.S. as a result of medication nonadherence.
ACCESSION #
84964572

 

Related Articles

  • Pharmacies & Drug Stores Industry (NAICS 44611).  // United States Pharmacies & Drug Stores Industry Capital & Expens;2012, preceding p1 

    This publication presents a market report on the U.S. pharmacies and drug stores industry. It contains a users' guide, industry definition and terms, and related industries. Several charts are also presented that show industry figures in 2011, 2012 and 2013, including estimated number of...

  • Should we pay the patient? Review of financial incentives to enhance patient compliance. Giuffrida, Antonio; Torgerson, David J. // BMJ: British Medical Journal (International Edition);09/20/97, Vol. 315 Issue 7110, p703 

    Determines whether financial incentives can increase patients' compliance with healthcare treatments. Identification of studies; Description of interventions; Effectiveness of monetary incentives.

  • Biotechs Increased R&D Spending 9% in 2011, Report Finds.  // MondayMorning;6/25/2012, Vol. 20 Issue 25, p1 

    The article offers information on a report by Ernst & Young LLP which depicts an increase in research and development expenditure of biotechnology companies of the U.S. for 2011 after a steep drop in 2009. It mentions that the revenue in the industry rose by 10 percent in 2011. It adds that the...

  • CORPORATE.  // MondayMorning;4/18/2011, Vol. 18 Issue 15, p2 

    The article offers news briefs related to the U.S. pharmaceutical industry. Roche Holding AG said that its first-quarter 2011 sales fell 9% with the decline in its revenue from the Avastin tumor drug and a stronger Swiss franc. Merck & Co. will resolve an arbitration dispute with Johnson &...

  • Pharma at the Crossroads. Sollazzo, Maurizio; Pippitt, Jeanine; Luchino, Paul // Contract Pharma;Mar2012, Vol. 14 Issue 2, p64 

    The article discusses the condition of the pharmaceutical industry in the U.S. which has been challenged by the declining profits, dropping revenues and increasing consumer demand. It highlights the significance of the Laboratory Asset Management Program that has represented as a first step...

  • AmerisourceBergen Corporation SWOT Analysis.  // AmerisourceBergen Corporation SWOT Analysis;Jun2013, p1 

    The article presents information on Chesterbrook, Pennsylvania-based AmerisourceBergen Corp., a pharmaceutical firm which offers drug distribution and related services to healthcare providers and pharmaceutical manufacturers in the U.S., Canada and other markets. The company's strengths and...

  • Fraud, Waste, and Abuse. Paul, Reid // Pharmaceutical Representative;Mar2011, Vol. 41 Issue 3, p5 

    The article discusses issues surrounding the pharmaceutical industry in the U.S. It highlights the effort of legislators to look for new ways to boost revenue such as user fees and court settlement in line with a 2.7 trillion dollar budget proposal and a projected debt of 1.1 trillion dollars....

  • The patent cliff steepens. Harrison, Charlotte // Nature Reviews Drug Discovery;Jan2011, Vol. 10 Issue 1, p12 

    The article reports that many drugs in the U.S. including Lipitor from Pfizer Inc. and Plavix from Sanofi-Aventis/Bristol-Myers Squibb, are facing expiry of their patents in the next 2 years. According to Michael Hay, an analyst at Sagient Research Systems, the patent cliff facing the industry...

  • Medical Stock Spotlight.  // MondayMorning;7/23/2012, Vol. 20 Issue 29, p1 

    The article reports on the performance of the stocks of various pharmaceutical companies in the U.S. It mentions that Alnylam Pharmaceuticals Inc.'s stocks have improved by 50 percent, following the promise shown by its drug to treat an organ-damaging hereditary disorder during clinical trials....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics